{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T08:51:40.523577+00:00","company":{"ticker":"ACET","cik":1720580,"company_name":"Adicet Bio, Inc."},"pagination":{"limit":100,"returned":10,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"governance_change","fact_key":"c3af50c57904024b0922a31768748e4747de0978","cik":1720580,"ticker":"ACET","company_name":"Adicet Bio, Inc.","filed_at":"2025-12-29T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-12-30","item_codes_triggered":["5.03"],"summary_text":"Effective as of December 30, 2025, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation to effect a 1-for-16 reverse stock split of its common stock."},"claim":"Adicet Bio, Inc.: Effective as of December 30, 2025, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation to effect a 1-for-16 reverse stock split of its common stock (effective 2025-12-30).","evidence_excerpt":"On December 26, 2025, Adicet Bio, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Restated Certificate of Incorporation, to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-332343","anchor_url":"https://secwatch.observer/filing/0001193125-25-332343#claim-c3af50c57904024b0922a31768748e4747de0978","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1720580/000119312525332343/0001193125-25-332343-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"a16a099b7102d8204337539302f805eed28f16c1","cik":1720580,"ticker":"ACET","company_name":"Adicet Bio, Inc.","filed_at":"2025-10-07T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2026-04-06","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-10-07","notice_type":"extension_granted","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5450(a)(1)","5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Adicet Bio, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-233427","anchor_url":"https://secwatch.observer/filing/0001193125-25-233427#claim-a16a099b7102d8204337539302f805eed28f16c1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1720580/000119312525233427/0001193125-25-233427-index.htm"},{"fact_type":"restructuring_charge","fact_key":"73a5186b9b506845680ec78ed1e7b516389f37ee","cik":1720580,"ticker":"ACET","company_name":"Adicet Bio, Inc.","filed_at":"2025-07-23T23:59:59+00:00","payload":{"affected_area":null,"charge_text":"approximately $2.3 million","effective_date":"2025-07-22","event_type":"restructuring","headcount_text":"approximately 30% of the Company’s current employee base","item_codes_triggered":["2.05"]},"claim":"Adicet Bio, Inc. announced a restructuring with charges of approximately $2.3 million (approximately 30% of the Company’s current employee base).","evidence_excerpt":"On July 22, 2025, the Board of Directors of Adicet Bio, Inc. (the Company or Adicet) approved a reduction in its workforce by approximately 30% of the Company’s current employee base in connection with its strategic pipeline prioritization, as disclosed under Item 8.01 of this Current Report on Form 8-K. This workforce reduction will be substantially completed by the end of the third quarter of 2025. As a result of these actions, the Company expects to incur personnel-related restructuring charges of approximately $2.3 million in connection with one-time employee termination cash expenditures, including severance and other benefits, which are expected to be substantially incurred in the third quarter of 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-25-097881","anchor_url":"https://secwatch.observer/filing/0000950170-25-097881#claim-73a5186b9b506845680ec78ed1e7b516389f37ee","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017025097881/0000950170-25-097881-index.htm"},{"fact_type":"executive_change","fact_key":"571ec5293b","cik":1720580,"ticker":"ACET","company_name":"Adicet Bio, Inc.","filed_at":"2025-04-17T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-04-17","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael Grissinger was appointed as Director at Adicet Bio, Inc..","evidence_excerpt":"On April 16, 2025, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Michael Grissinger to the Board, effective as of April 17, 2025, to fill the vacancy resulting from Dr. Gordon’s resignation.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-054995","anchor_url":"https://secwatch.observer/filing/0000950170-25-054995#claim-571ec5293b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017025054995/0000950170-25-054995-index.htm"},{"fact_type":"executive_change","fact_key":"bb7607e447","cik":1720580,"ticker":"ACET","company_name":"Adicet Bio, Inc.","filed_at":"2025-04-17T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-04-17","interim":false,"role":"Director","role_category":"director","successor_name":"Michael Grissinger","successor_named":true},"claim":"Carl L. Gordon resigned as Director at Adicet Bio, Inc..","evidence_excerpt":"On April 14, 2025, Carl L. Gordon, Ph.D., a Class II member of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), notified the Company of his resignation from the Board and Compensation Committee of the Board (the “Compensation Committee”), effective on April 17, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-054995","anchor_url":"https://secwatch.observer/filing/0000950170-25-054995#claim-bb7607e447","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017025054995/0000950170-25-054995-index.htm"},{"fact_type":"executive_change","fact_key":"9c54fc336d","cik":1720580,"ticker":"ACET","company_name":"Adicet Bio, Inc.","filed_at":"2024-08-19T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-19","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Lloyd Klickstein was appointed as Director at Adicet Bio, Inc..","evidence_excerpt":"the Board appointed Lloyd Klickstein, M.D., Ph.D. to the Board, effective as of August 19, 2024, to fill the vacancy on the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-098485","anchor_url":"https://secwatch.observer/filing/0000950170-24-098485#claim-9c54fc336d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024098485/0000950170-24-098485-index.htm"},{"fact_type":"executive_change","fact_key":"62173e1aa4","cik":1720580,"ticker":"ACET","company_name":"Adicet Bio, Inc.","filed_at":"2024-08-19T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-08-19","interim":false,"role":"Director","role_category":"director","successor_name":"Lloyd Klickstein","successor_named":true},"claim":"Michael Kauffman resigned as Director at Adicet Bio, Inc..","evidence_excerpt":"Michael Kauffman, M.D., Ph.D., a Class III member of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), notified the Company of his resignation from the Board and Nominating and Corporate Governance Committee (the “NCG Committee”), effective as of August 19, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-098485","anchor_url":"https://secwatch.observer/filing/0000950170-24-098485#claim-62173e1aa4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024098485/0000950170-24-098485-index.htm"},{"fact_type":"earnings_release","fact_key":"3bd6e01bdda89a4e979be66b3687f3d69455729b","cik":1720580,"ticker":"ACET","company_name":"Adicet Bio, Inc.","filed_at":"2024-05-14T23:59:59+00:00","payload":{"eps_text":"$0.35 per basic and diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $28.0 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-14","result_type":"reported_results","revenue_text":null},"claim":"Adicet Bio, Inc. reported first quarter ended March 31, 2024 results: net income net loss of $28.0 million, EPS $0.35 per basic and diluted share.","evidence_excerpt":"Net loss for the three months ended March 31, 2024 was $28.0 million, or a net loss of $0.35 per basic and diluted share","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-24-059496","anchor_url":"https://secwatch.observer/filing/0000950170-24-059496#claim-3bd6e01bdda89a4e979be66b3687f3d69455729b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024059496/0000950170-24-059496-index.htm"},{"fact_type":"material_agreement","fact_key":"98b51c8709b156d4a712b78230e6083210e9875f","cik":1720580,"ticker":"ACET","company_name":"Adicet Bio, Inc.","filed_at":"2024-03-22T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Sales Agreement","agreement_type":"atm_program","counterparty":"Jefferies LLC","effective_date":"2024-03-22","item_codes_triggered":["1.01"],"value_text":"3.0% of the gross proceeds"},"claim":"Adicet Bio, Inc. entered into Sales Agreement with Jefferies LLC valued at 3.0% of the gross proceeds (effective 2024-03-22).","evidence_excerpt":"On March 22, 2024, Adicet Bio, Inc. (the “Company”) entered into an Open Market Sales Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) to sell shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), from time to time, through an “at the market” equity offering program under which Jefferies will act as sales agent or principal.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-035366","anchor_url":"https://secwatch.observer/filing/0000950170-24-035366#claim-98b51c8709b156d4a712b78230e6083210e9875f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024035366/0000950170-24-035366-index.htm"},{"fact_type":"earnings_release","fact_key":"605f85b6e127e0817550f8a7832bf3206ac77d49","cik":1720580,"ticker":"ACET","company_name":"Adicet Bio, Inc.","filed_at":"2024-03-19T23:59:59+00:00","payload":{"eps_text":"$0.69 per basic and diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the three months ended December 31, 2023 was $29.5 million, or a net loss of $0.69 per basic and diluted sh","period_text":"fourth quarter and year ended December 31, 2023","report_date":"2024-03-19","result_type":"reported_results","revenue_text":null},"claim":"Adicet Bio, Inc. reported fourth quarter and year ended December 31, 2023 results: net income Net loss for the three months ended December 31, 2023 was $29.5 million, or a net loss of $0.69 per basic and diluted sh, EPS $0.69 per basic and diluted share.","evidence_excerpt":"On March 19, 2024, Adicet Bio, Inc. announced its financial results for the quarter and year ended December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-033476","anchor_url":"https://secwatch.observer/filing/0000950170-24-033476#claim-605f85b6e127e0817550f8a7832bf3206ac77d49","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024033476/0000950170-24-033476-index.htm"}]}